Compendium

Biomaterials — Implants, Tissue Engineering, Drug Delivery

28 min read

Biomaterials

Biomaterials are engineered materials designed to interface with biological systems for therapeutic or diagnostic purposes. The field spans implantable hardware (joint replacements, stents, pacemakers, dental restorations), short-term contact devices (catheters, sutures, contact lenses), drug-delivery vehicles (nanoparticles, depots), and tissue-engineering scaffolds. The unifying constraint is that the material must function mechanically while maintaining acceptable biological compatibility — neither toxic nor immunogenic enough to compromise the host. Units are SI primary; clinical/US conventions in parentheses where used in industry.

1. Definition and Classes

The Williams definition (Chester 1986, revised 2009): “A biomaterial is a substance that has been engineered to take a form which, alone or as part of a complex system, is used to direct the course of any therapeutic or diagnostic procedure, by control of interactions with components of living systems.” Roughly 8 to 10 million implant procedures occur worldwide each year.

1.1 Classes by material family

  • Metals: 316L stainless, Ti and Ti-alloys, Co-Cr-Mo alloys, nitinol (NiTi), tantalum, magnesium (resorbable)
  • Polymers: UHMWPE, PMMA, silicone, PEEK, polyurethanes, PGA, PLA, PLGA, PCL, hydrogels (PHEMA, PEG, alginate, hyaluronic acid), polypyrrole, parylene
  • Ceramics: alumina, zirconia (Y-TZP), hydroxyapatite (HA), tricalcium phosphate (TCP), 45S5 Bioglass, carbon (pyrolytic, DLC)
  • Composites: GFRP/CFRP plates, fiber-reinforced PEEK, HA-PLA scaffolds
  • Natural / biologic: collagen, fibrin, chitosan, silk fibroin, gelatin, decellularized ECM, alginate (algae), elastin

1.2 Classes by tissue response (Hench classification)

  • Bioinert: minimal interaction with host tissue, forms fibrous capsule. Examples: alumina, Ti, 316L SS, UHMWPE, PMMA, PEEK.
  • Bioactive: chemically bonds to surrounding tissue (especially bone) via a reactive surface layer. Examples: Bioglass 45S5 (Hench 1969, University of Florida), HA, A-W glass-ceramic (Cerabone).
  • Bioresorbable: dissolves or hydrolyzes in vivo, replaced by host tissue. Examples: PLA, PGA, PLGA, PCL, β-TCP, Mg alloys, calcium sulfate.

1.3 Generations of biomaterials (Hench & Polak 2002 framework)

  • 1st generation (1960s–1970s): bioinert — Charnley hip, early dialysis tubing
  • 2nd generation (1980s–1990s): bioactive and resorbable — HA-coated implants, bioglass, resorbable sutures
  • 3rd generation (2000s–present): bioactive AND resorbable, intended to stimulate specific cellular response — tissue-engineering scaffolds, gene-activated matrices, smart drug delivery

2. Metallic Biomaterials

2.1 316L stainless steel (ASTM F138/F139)

Composition: Fe-17Cr-12Ni-2.5Mo-low C (<0.030%). The “L” denotes low carbon to suppress sensitization (Cr-carbide precipitation at grain boundaries → IGSCC in body fluids). Introduced for orthopedic implants in the 1930s (Sherman vanadium steel preceded it; Strauss 316 took over). E ≈ 200 GPa, σ_y 170–310 MPa (annealed) up to >800 MPa (cold-worked). Cheap but susceptible to crevice corrosion and Ni-ion release (Ni allergy in ~15% of women, ~3% of men). Today mostly used for temporary implants (bone plates, screws) where Ti cost is not justified.

2.2 Titanium and titanium alloys

  • CP Ti (Grades 1–4): pure titanium, varying O content. E ≈ 110 GPa, σ_y 170–480 MPa. Excellent biocompatibility; used for dental implants and osseointegrating screws.
  • Ti-6Al-4V (Grade 5, ASTM F136 ELI = extra-low-interstitial): α+β alloy, σ_y ≈ 800 MPa, σ_UTS ≈ 900 MPa, E ≈ 113 GPa. Dominant in orthopedic stems and dental abutments. Concerns about long-term Al and V release have driven interest in V-free alloys.
  • Ti-6Al-7Nb (ASTM F1295): Nb replaces V. Used in European hip stems (Sulzer Protasul-100).
  • β-titanium alloys (Ti-Nb-Zr, Ti-Mo, Ti-13Nb-13Zr ASTM F1713, Ti-12Mo-6Zr-2Fe — TMZF): E as low as 55–80 GPa, closer to cortical bone (~17 GPa) — reduces stress shielding (Wolff’s law-driven bone resorption around stiff implants). β-21S and Gum Metal (Toyota Central R&D 2003) extend this further.

Osseointegration: Per-Ingvar Brånemark (Gothenburg, 1965, accidentally with a titanium-housed bone microscope chamber) showed that bone forms a direct mineralized interface with titanium without intervening fibrous tissue. This founded the modern dental-implant industry (Nobel Biocare 1981 commercialization of the Brånemark System) and migrated to orthopedics, where porous and HA-coated Ti surfaces became standard.

2.3 Cobalt-chromium-molybdenum (Co-Cr-Mo)

  • F75 (cast Co-28Cr-6Mo, ASTM F75): tradition for hip femoral heads and articular knee components. σ_y ≈ 450 MPa, but coarse grains.
  • F1537 (wrought Co-28Cr-6Mo, ASTM F1537): hot-forged, finer microstructure, σ_y ≈ 750 MPa.
  • F90 (Co-Cr-W-Ni, Stellite 25): high cold-worked strength, used for stems.

Co-Cr is wear-resistant (HV 350–450), corrosion-resistant in chloride, and dominated metal-on-metal hip bearings — until the ASR (DePuy Articular Surface Replacement) recalls in 2010 over Co/Cr ion release and pseudotumors. Today Co-Cr-Mo is still standard for the femoral side of knee replacements articulating against UHMWPE.

2.4 Nitinol (Ni-Ti, NiTi)

Discovered at the Naval Ordnance Laboratory (Buehler 1959, hence “NOL” → Nitinol). Two unique behaviors:

  • Shape memory effect: martensitic deformation recovered on heating through A_f
  • Superelasticity: pseudoelastic recovery of strains up to ~8% by stress-induced martensite (above A_f)

Used in self-expanding stents (Wallstent Schneider/Boston Scientific 1986; Palmaz-Schatz balloon-expandable was 316L SS 1987, but later Nitinol Smart, Protégé, Zilver took share), embolic filters (IVC filters Greenfield, Bard Recovery), orthodontic archwires (3M Unitek 1972), endodontic files, vascular guidewires, and the Amplatzer septal-defect occluder (Amplatz, AGA Medical, 1995; St. Jude/Abbott now).

2.5 Tantalum

Very corrosion-resistant; the porous Trabecular Metal (Zimmer, originally Implex) has 75–80% porosity with 550 μm pores, mimics trabecular bone modulus, used for revision hip/knee components.

2.6 Magnesium (bioresorbable metal)

E ≈ 45 GPa (close to bone), density 1.74 g/cm³, dissolves in body fluid (Mg → Mg²⁺ + 2e⁻; H₂ evolution is a complication). Magmaris bioresorbable Mg scaffold (Biotronik) received CE mark 2016. Resorbable Mg screws (MAGNEZIX, Syntellix) for fracture fixation, especially pediatric, in EU.

3. Polymer Biomaterials

3.1 UHMWPE — the gold-standard joint bearing

Ultra-high-molecular-weight polyethylene, MW 3–6 × 10⁶ g/mol, semicrystalline. Sir John Charnley (Wrightington Hospital, UK) introduced UHMWPE acetabular cups in 1962 after PTFE (Teflon) failures from severe wear in his 1958–60 trials. The “Charnley Low Friction Arthroplasty” stainless steel stem + 22.225 mm head + UHMWPE cup + PMMA cement became the template for all subsequent hip replacements.

Wear-debris-induced osteolysis emerged as the dominant failure mode (1980s–90s). Highly crosslinked UHMWPE (HXLPE) — gamma- or e-beam-irradiated 50–100 kGy, then melted or annealed to quench residual radicals — reduced wear by 5–10× clinically. Introduced commercially around 1998 (Stryker Crossfire, Zimmer Longevity, DePuy Marathon). Second-generation HXLPE incorporates vitamin E (α-tocopherol, antioxidant) to suppress oxidation (Biomet E1, Zimmer Vivacit-E, Stryker X3 with sequential anneal).

3.2 PMMA bone cement

Sir John Charnley adapted dental PMMA (Kulzer Palacos) for hip fixation in 1958. Pre-mixed powder (PMMA beads + benzoyl peroxide initiator + BaSO₄ radiopacifier ± gentamicin antibiotic) + MMA monomer liquid → exothermic radical polymerization (peak ~80 °C, 5–10 min). Modulus ~2–3 GPa. Failures from cement-bone interface mantle defects drove the third-generation cementing technique (pulsatile lavage, vacuum mixing, retrograde injection — Ling/Exeter philosophy).

3.3 PMMA in ophthalmic IOLs

Harold Ridley (St. Thomas’ Hospital London) implanted the first intraocular lens in 1949 after observing that Spitfire pilots tolerated PMMA canopy shards in their eyes. PMMA IOLs were standard until foldable hydrophilic and hydrophobic acrylates (Alcon AcrySof 1994) took over.

3.4 Bioresorbable polyesters: PGA, PLA, PLGA, PCL

Aliphatic polyesters that degrade by hydrolysis of the backbone ester linkages, mostly bulk erosion (water penetrates faster than degradation):

PolymerT_g (°C)T_m (°C)Degradation
PGA35–40220–2256–12 weeks
L-PLA60–65175–18024+ months
D,L-PLA (amorphous)55n/a12–16 months
PLGA (50:50)45–55n/a1–2 months
PLGA (75:25)50–55n/a4–5 months
PLGA (85:15)50–55n/a5–6 months
PCL−60602–3 years
PHB / PHBV0 (PHB 5)1751+ year

PGA-based sutures: Davis & Geck Dexon (1970, first synthetic absorbable); PGA-co-trimethylene carbonate Maxon (Tyco/Covidien); PGA-co-caprolactone Monocryl (Ethicon). PLGA: Vicryl (Ethicon, polyglactin 910, 90:10 PGA:LLA), Vicryl Rapide. PCL/PGA: Monocryl Plus antibacterial.

Cardiovascular: Abbott Absorb BVS (PLLA stent, first FDA approved 2016, withdrawn 2017 over thrombosis rates). Resorbable orthopedic pins/screws/anchors (Arthrex BioComposite, Biomet Bio-Statak).

3.5 Silicone (polydimethylsiloxane, PDMS)

Cross-linked PDMS, biostable, hydrophobic, low T_g (−125 °C — rubbery at body T). First medical use: silicone heart-valve poppets and cosmetic implants in the 1950s. The Cronin-Gerow gel-filled breast implant (1962, Dow Corning) launched mammary implantation. The 1992 FDA moratorium followed connective-tissue-disease claims (later epidemiologically refuted); silicone gel implants returned to market 2006 with Mentor MemoryGel and Allergan Natrelle. Other uses: maxillofacial prosthetics, finger joints (Swanson 1962), hydrocephalus shunts (Holter valve 1956, after engineer John Holter’s son), drainage catheters, pacing leads (insulator), penile/testicular prosthetics, contact lenses (silicone hydrogels), and microfluidic chips for research.

3.6 PEEK (polyetheretherketone)

Aromatic semicrystalline thermoplastic, T_m 343 °C, T_g 143 °C, E ≈ 3.6 GPa. Invictrus implant grade by Invibio (now Solvay) released 1998. Radiolucent (does not obscure CT/MRI), so widely used for spinal interbody fusion cages (Medtronic Capstone, Stryker AVS) replacing Ti cages. Carbon-fiber-reinforced PEEK (CFR-PEEK) for fracture-fixation plates and dental abutments approaches Ti modulus.

3.7 Polyurethanes

Segmented block copolymers (hard + soft segments) — combine elastomeric behavior with biostability. Pellethane and Tecothane lines (Lubrizol) used for pacing-lead insulation, catheter shafts, and the LVAD blood-contact diaphragm (HeartMate XVE flexing diaphragm was polyurethane; current HeartMate III bearings differ). Susceptible to environmental stress cracking (ESC) and metal-ion-oxidation (MIO) from cobalt in adjacent conductor coils — drove move to polycarbonate-urethanes (Bionate, DSM).

3.8 Hydrogels

Crosslinked hydrophilic polymer networks that swell to >30% water by weight. Drago Wichterle in Prague (1960, with student Lim) polymerized pHEMA into the first hydrogel contact lens; Bausch & Lomb’s Soflens (1971, FDA approved) made daily soft contact lenses mainstream. Lens water contents now range from 38% (pHEMA) to >75% (high-water-content ionic). Silicone hydrogels (Johnson & Johnson Acuvue Oasys, CIBA/Alcon Air Optix) deliver 5–7× higher oxygen transmissibility (Dk/t) for extended wear.

Other hydrogel platforms:

  • PEG (polyethylene glycol): highly biocompatible, antifouling (PEGylated bioconjugates), photocrosslinkable diacrylate (PEGDA), thiol-ene click-able. Hubbell, Hennink, Anseth-group chemistries.
  • PEG-RGD: bioactive functionalized hydrogels for tissue engineering (Hubbell/EPFL).
  • Alginate: extracted from brown algae, Ca²⁺-crosslinked, used for cell encapsulation (encapsulated islet cells — Lanza/Vacanti, then ViaCyte/Encellin clinical attempts).
  • Hyaluronic acid (HA): GAG, used as ophthalmic viscosurgical (Healon — Pharmacia 1979) and intra-articular injection (Synvisc, Genzyme/Sanofi for osteoarthritis).
  • Chitosan: deacetylated chitin from crustacean shells; wound dressings (HemCon hemostatic).
  • Methocel / methylcellulose, gelatin, fibrin: injectable scaffolds and surgical sealants.

3.9 Conductive polymers

Polypyrrole, PEDOT:PSS, polyaniline — used for neural-electrode coatings to bridge stiffness mismatch and stabilize chronic recording (Martin, Cui labs). Wyss Center, Neuralink-style flexible electrodes incorporate PEDOT:PSS on Pt micro-arrays.

4. Ceramic Biomaterials

4.1 Alumina (Al₂O₃)

High-purity (>99.5%) sintered α-alumina used for femoral heads (Mittelmeier ceramic-on-ceramic hip 1974, Pierre Boutin Sarl 1971), dental crowns. E ≈ 380 GPa, σ_c 4 GPa compressive, σ_flex 400 MPa, K_IC ≈ 4 MPa·m^0.5, HV ~1800. Excellent wear-resistance but brittle — sized to extremely low surface roughness (Ra < 0.02 μm) since flaws control strength.

4.2 Zirconia (ZrO₂)

Yttria-stabilized tetragonal polycrystalline (Y-TZP), 3 mol% Y₂O₃. Transformation toughening: stress-induced t → m martensitic transformation at the crack tip absorbs energy. K_IC ≈ 9–15 MPa·m^0.5, σ_flex 1000–1500 MPa. Dental crowns and bridges (Procera by Nobel Biocare 1993, CAD/CAM blocks by Ivoclar Vivadent IPS e.max ZirCAD, 3M Lava). Femoral heads (Prozyr by St. Gobain) recalled in 2001 after a sintering-furnace QC issue caused in-vivo low-temperature degradation (LTD) — humid surface aging tetragonal → monoclinic, microcracking, spontaneous fracture. Modern Y-TZP and Ce-TZP-Al₂O₃ composites (Biolox Delta, CeramTec — alumina matrix with zirconia + chromia + strontia) are the standard for ceramic hip heads.

4.3 Hydroxyapatite (HA)

Ca₁₀(PO₄)₆(OH)₂, the mineral phase of bone and dental enamel. Bioactive — forms direct chemical bond with bone via a calcium-deficient apatite layer. Used as: dense ceramic bone substitute (Pyrost, Surgibone limited), porous granules (BoneSource, OsteoGen), plasma-sprayed coating on Ti hip stems and dental implants (improves early osseointegration), composite filler in resorbable scaffolds (e.g., Inion CPS, OsSatura PCL/HA from Xilloc).

4.4 Bioglass 45S5 (Hench glass)

Composition (wt%): 45 SiO₂, 24.5 CaO, 24.5 Na₂O, 6 P₂O₅. Larry Hench at University of Florida (1969, funded by US Army Materials and Mechanics Research Center after Vietnam-era amputation challenges) demonstrated direct bone-bonding via a surface reaction layer (alkali leach → silica gel → Ca-P precipitation → biological apatite). FDA approval as MEP (middle-ear ossicle replacement) 1985; ERMI/Endo-OssBio (dental ridge), PerioGlas (periodontal) commercialized by USBiomaterials. NovaBone Dental Putty and NovaMin remineralizing toothpaste additive (now Sensodyne Repair & Protect, GSK 2010) commercialize the principle.

4.5 Tricalcium phosphate (TCP) and biphasic calcium phosphate (BCP)

β-TCP, Ca₃(PO₄)₂, more soluble than HA — resorbable bone substitute (Vitoss, Stryker). BCP (HA/β-TCP mixture, e.g., 60/40) tunes resorption to bone-formation rate (Triosite, Zimmer). Synthetic alternatives to autograft for spinal fusion and bone-void filling.

4.6 Carbon

Pyrolytic carbon (LTI, low-temperature isotropic): turbostratic structure, deposited on graphite substrates, exceptional blood compatibility. Used for mechanical heart valve leaflets — Medtronic Hall, St. Jude Medical bileaflet (1977, FDA 1982), CarboMedics, On-X (CryoLife). Diamond-like carbon (DLC) coatings on knees and stents reduce wear.

5. Cell–Material Interactions

5.1 Protein adsorption (Vroman effect)

Within seconds of blood contact, abundant low-affinity proteins (albumin, IgG) adsorb, then are progressively displaced by higher-affinity, lower-abundance proteins (fibrinogen, then high-molecular-weight kininogen and factor XII) — the Vroman effect (Leo Vroman, NIH 1962). The final adsorbed protein layer rather than the bare material is what cells “see.”

5.2 Focal adhesions

Cells anchor to ECM proteins (or adsorbed protein layers) via heterodimeric integrin receptors (α + β subunits — humans have 24 α/β combinations, e.g., α5β1 for fibronectin RGD, α2β1 for collagen GFOGER). Integrin clustering recruits a multi-protein plaque: talin → vinculin → paxillin → FAK → actin cytoskeleton. This forms a mechanotransduction node — both transmitting traction force to the substrate and signaling via FAK/Src phosphorylation.

5.3 Durotaxis (substrate stiffness sensing)

Cells migrate up stiffness gradients (Lo et al., Discher lab, 2000). Engler, Discher & Sweeney (Cell 2006) showed that mesenchymal stem cells (MSCs) on polyacrylamide gels of variable modulus differentiate by stiffness alone: ~0.1–1 kPa → neurogenic, 8–17 kPa → myogenic, 25–40 kPa → osteogenic. Established stiffness as an independent differentiation cue and launched the field of mechanobiology.

5.4 Contact guidance (topography)

Cells align along grooves, ridges, or fibers of width 5–50 μm. Pioneered by Curtis & Wilkinson (Glasgow, 1970s) with photolithographically defined polymer substrates. Now leveraged in nerve-conduit and tendon-scaffold design (e.g., parallel-aligned electrospun fibers for axon guidance).

5.5 Pore size for tissue ingrowth

  • Bone ingrowth into porous scaffolds: 100–500 μm (sweet spot 200–300 μm)
  • Vascular ingrowth (capillaries): >40 μm
  • Fibrovascular tissue: 50–200 μm
  • Cellular bridging without vascularization: 5–15 μm

These have driven design of porous Ti acetabular cups (Stryker Tritanium, Smith & Nephew StikTite), porous tantalum (Trabecular Metal), and 3D-printed lattice implants.

6. Surface Modification

6.1 Plasma treatments

Oxygen, argon, or ammonia plasma (low pressure, RF-driven) oxidizes the surface, increases wettability, introduces functional groups (-OH, -COOH, -NH₂) for subsequent grafting. Corona treatment is a higher-pressure variant for polymer films.

6.2 Silanization (SAM, self-assembled monolayers)

APTES (3-aminopropyltriethoxysilane), OTS (octadecyltrichlorosilane) for hydrophobic monolayers. Hydroxylated surfaces (Si-OH, Ti-OH after acid etch or plasma) react with the alkoxysilane to give covalent siloxane bonds. Used to introduce amine, thiol, or aldehyde handles for biomolecule conjugation.

6.3 PEGylation (antifouling)

Grafted polyethylene glycol chains (MW 2–10 kDa) reduce protein adsorption by steric repulsion (“brush” regime — Alexander–de Gennes). Foundational work by Whitesides/Mrksich (Harvard) on alkanethiol-OEG SAMs on Au. Underlies PEG-coated implantable sensors (Medtronic Guardian CGM, Abbott Freestyle Libre membranes use polyzwitterionic chemistry as an antifouling alternative).

6.4 Bioactive coatings

  • RGD peptide grafting: tripeptide motif (Arg-Gly-Asp) from fibronectin, recognized by integrins α5β1 and αvβ3. Pierschbacher & Ruoslahti 1984 (La Jolla). Used to render inert hydrogels cell-adhesive without full ECM protein.
  • Heparin coating: covalently bound heparin on blood-contact surfaces (Carmeda BioActive Surface used in Medtronic oxygenator membranes and stents).
  • Hydroxyapatite plasma spray: porous HA layer 50–200 μm thick on Ti stems; FDA approved late 1980s, dominant for cementless hip stems (Stryker Omnifit-HA, Zimmer VerSys HA).

6.5 Diamond-like carbon (DLC)

Hard, low-friction, hydrophobic. Tribological coating on bearing surfaces. Sirona, Implant Direct dental abutments.

7. Sterilization

Mandatory before implantation. Choice of method must not degrade the material.

MethodConditionsProsCons
Autoclave (steam)121 °C, 15 psi (103 kPa), 15 minCheap, no residuesDamages thermoplastics, biologics, electronics
Dry heat160 °C, 2 hPenetrates powdersEven harsher on polymers
Ethylene oxide (EtO)30–60 °C, EtO gas, 12 h cycle + aerationLow-T, broad compatibilityMutagen, carcinogen — long aeration to drop residuals below ISO 10993-7 limits
Gamma (Co-60)25 kGy typicalPenetrates packaged trays, no temp/moistureChain scission of polymers (PE, PP, PTFE), oxidation of UHMWPE → late osteolysis
E-beam25 kGy, fast scanHigh throughput, less dose-rate oxidationLimited penetration (typically <50 mm equivalent)
Vaporized hydrogen peroxide (VHP / Sterrad)Low-T plasma, H₂O₂ vaporMaterial-friendly, fast cyclePenetration limits (cannot use cellulosic packaging); STERIS V-PRO line
UV-C254 nmSurface onlyLow penetration; sometimes used for surface re-sterilization in dental
Supercritical CO₂40 °C, 100 bar CO₂ ± peracetic acidPreserves biologics (ECM, growth factors)Newer; NovaSterilis used for allograft tissue

Gamma irradiation of UHMWPE in air was implicated in the 1980s–90s wave of accelerated wear and osteolysis. Modern UHMWPE is irradiated in inert gas, then thermally treated.

8. Implant Performance and the Foreign Body Response

8.1 Wound healing sequence

Hemostasis (seconds–minutes) → acute inflammation (PMNs, hours–days) → chronic inflammation (macrophages, days–weeks) → granulation/repair → remodeling.

8.2 Foreign body response (FBR)

Macrophages encountering an indigestible implant (>10 μm) fuse into foreign-body giant cells (FBGCs), which secrete TGF-β recruiting fibroblasts → fibrous encapsulation (collagenous capsule 20–500 μm thick). Capsule contracts in some patients (notably around breast implants — Baker grades I–IV).

8.3 Wear debris and osteolysis

UHMWPE wear particles 0.1–1 μm phagocytosed by macrophages → release of TNF-α, IL-1, IL-6, RANKL → osteoclast activation → peri-prosthetic bone resorption (osteolysis) → aseptic loosening. Historically the dominant failure mode of hip arthroplasty (Willert, Goldring; Harris 1995). HXLPE addressed this for most patients.

8.4 Other complications

  • Infection: 0.5–2% in primary joints, ~5× higher in revisions. Staphylococcal biofilms are particularly resistant.
  • Thrombosis on blood-contact surfaces: anticoagulation, surface coatings, smoothness reduce risk.
  • Corrosion: especially trunnion (taper) corrosion in modular metal-on-metal hips (DePuy ASR recall 2010).
  • Stress shielding: stiff implants offload adjacent bone, leading to disuse osteopenia (Wolff’s law).

9. Regulation and Standards

9.1 FDA pathways (US)

  • Class I: low-risk, general controls (bandages, tongue depressors)
  • Class II: moderate-risk, 510(k) premarket notification — claim substantial equivalence to a “predicate” device. Most ortho implants, catheters, infusion pumps.
  • Class III: high-risk, Premarket Approval (PMA) — requires clinical trials. Heart valves, implantable defibrillators, breast implants since 2000.
  • De Novo: novel low-to-moderate-risk devices without a predicate.
  • Humanitarian Device Exemption (HDE): rare conditions (<8,000/year).
  • Breakthrough Devices Program (2015 expansion): priority review for life-threatening conditions.

9.2 EU regulation

  • MDD 93/42/EEC was replaced by MDR (EU) 2017/745 (entered force 2021; transitional extension to 2027–2028). Notified Bodies issue CE mark. Implantable devices typically Class IIb or III.
  • IVDR (EU) 2017/746 for in vitro diagnostics.
  • EUDAMED database for device traceability.

9.3 Quality management

  • ISO 13485: medical-device quality management system. Compatible-but-distinct from ISO 9001; explicit risk and design-control requirements.
  • ISO 14971: medical-device risk management (FMEA, hazard analysis).
  • 21 CFR Part 820: FDA Quality System Regulation (QSR), being harmonized to ISO 13485 as of the 2024 final rule (compliance 2026).

9.4 Biocompatibility — ISO 10993 series

The 23-part standard battery. Selection by contact category (surface / external-communicating / implant) × duration (limited <24 h / prolonged 24 h–30 d / long-term >30 d).

PartTopic
10993-1Evaluation and testing within risk-management framework
10993-3Genotoxicity, carcinogenicity, reproductive toxicity
10993-4Hemocompatibility
10993-5In vitro cytotoxicity (most common screen — L929 elution test)
10993-6Local effects after implantation
10993-7EtO sterilization residuals
10993-9Degradation products framework
10993-10Skin sensitization and irritation
10993-11Systemic toxicity
10993-12Sample preparation
10993-17Allowable limits for leachables
10993-18Chemical characterization (replaces and extends old 10993-19)

ISO 10993-1 was revised 2018, again 2024 — emphasis shifting from “default test everything” to risk-based chemical characterization (10993-18) plus targeted biological tests only where needed.

10. Implant Categories — Devices and Companies

10.1 Orthopedic — hip

Charnley LFA template (1962, Sir John Charnley) → modular cobalt or Ti stems with replaceable heads (CoCr, alumina, or zirconia) and UHMWPE or HXLPE liners in Ti or Tantalum cups.

Major OEMs (2024 market shares): DePuy Synthes (J&J — Corail, Pinnacle, Attune), Zimmer Biomet (Taperloc, G7, Trilogy, Persona), Stryker (Accolade II, MDM, Triathlon), Smith & Nephew (Anthology, R3, Polar), Medacta, Exactech, MicroPort, Aesculap (B. Braun).

10.2 Orthopedic — knee

Total knee replacement (TKR) replaces femoral condyles, tibial plateau, and patella. Posterior-cruciate-retaining vs posterior-stabilized vs ultracongruent designs.

Flagships: Stryker Triathlon, Zimmer NexGen and Persona, DePuy Attune, S&N Genesis II / Journey II.

10.3 Orthopedic — spine

Pedicle screws (Ti or PEEK), interbody fusion cages (PEEK, Ti, 3D-printed Ti lattice), motion-preserving cervical and lumbar disc replacements (Mobi-C ZimVie 2013, ProDisc, M6-C Orthofix, Activ-L), expandable cages, sacroiliac fusion implants (SI-BONE iFuse).

10.4 Cardiovascular — coronary stents

Generations:

  • Bare-metal stent (BMS): Palmaz-Schatz 1987 (Johnson & Johnson, 316L) — first FDA approval 1994.
  • Drug-eluting stent (DES) 1st-gen: Cypher (Cordis/J&J, sirolimus on parylene base, CE 2002, FDA 2003), Taxus (Boston Scientific, paclitaxel, 2004). Hugely reduced restenosis but late thrombosis concerns.
  • DES 2nd-gen: Xience (Abbott, everolimus on durable acrylic polymer on Co-Cr platform, 2008), Resolute (Medtronic, zotarolimus, BioLinx polymer), Promus (Boston Scientific, everolimus).
  • DES 3rd-gen: Synergy (Boston Sci, everolimus on bioresorbable PLGA), Orsiro (Biotronik, sirolimus, BIOlute PLLA coating), Ultimaster (Terumo).
  • Bioresorbable scaffold (BRS): Abbott Absorb (PLLA, FDA 2016, withdrawn 2017), Biotronik Magmaris (Mg, CE 2016), DESolve, Fantom — class still struggling with thrombosis vs metal DES.

10.5 Cardiovascular — heart valves

Mechanical:

  • Caged-ball: Starr-Edwards (1960, Albert Starr + Lowell Edwards, first commercial)
  • Tilting-disc: Björk-Shiley (1969 — later C-C ring fracture recall ~250 deaths)
  • Bileaflet pyrolytic carbon: St. Jude Medical (1977, FDA 1982, today Abbott), CarboMedics, On-X (CryoLife, lower target INR), ATS Medical (Medtronic).

Bioprosthetic (porcine or bovine pericardial):

  • Edwards Magna and Magna Ease, Inspiris Resilia
  • Medtronic Mosaic, Hancock II
  • Abbott Epic and Trifecta
  • TAVR (transcatheter aortic valve replacement): Edwards Sapien (1st-in-man Cribier 2002, FDA Sapien XT 2014; Sapien 3 and Sapien 3 Ultra are current), Medtronic CoreValve / Evolut, Abbott Navitor and Portico, Boston Scientific Acurate Neo2 (recalled in US 2024).
  • TMVR: Abbott Tendyne (CE), Medtronic Intrepid, Edwards EVOQUE.

10.6 Dental implants

Brånemark System (Nobel Biocare 1981), Straumann SLActive, Dentsply Sirona Astra Tech and Ankylos, Zimmer Biomet 3i, BioHorizons, Megagen (Korea), Osstem (Korea). Osseointegrated CP-Ti or Ti-6Al-4V root analog with abutment + crown. Surface treatments: SLA (sandblasted, large-grit, acid-etched — Straumann), TiUnite (anodized — Nobel), Osseospeed (HF-treated — Astra).

10.7 Ophthalmic

  • Intraocular lenses: Alcon AcrySof (hydrophobic acrylic, world-leading volume), Johnson & Johnson Tecnis, B&L enVista, Carl Zeiss CT Lucia. Multifocal, extended-depth-of-focus, and toric variants.
  • Contact lenses: J&J Vision Acuvue Oasys, Alcon Air Optix and Total1, CooperVision Biofinity, B&L Ultra. Mostly silicone hydrogels.
  • Glaucoma: trabecular bypass stents — iStent (Glaukos), Hydrus (Alcon, Ivantis).

10.8 Neuromodulation and neural interfaces

  • Cochlear implants: Cochlear Limited (Nucleus), Advanced Bionics (Sonova), MED-EL (Synchrony). Platinum stimulation arrays in silicone, intracochlear.
  • Deep brain stimulation (DBS): Medtronic Activa (1997 FDA for tremor, 2002 Parkinson’s; current Percept PC with sensing), Abbott Infinity, Boston Scientific Vercise. Ir/Pt electrodes on polyurethane lead.
  • Vagus nerve stimulation: LivaNova (formerly Cyberonics).
  • Spinal cord stimulation: Medtronic Intellis, Abbott Proclaim, Boston Scientific Spectra WaveWriter, Nevro Senza HF10.
  • Cortical recording (research): Utah Array (Blackrock Neurotech), Neuropixels (IMEC), Neuralink N1 (1024-channel flexible polymer threads, first human implant Jan 2024).

10.9 Cardiac rhythm management

Pacemakers: Wilson Greatbatch’s 1958 self-powered implantable pacemaker (Buffalo, NY) — used with surgeon William Chardack at the VA. Earl Bakken (Medtronic) had built a wearable battery-powered external one in 1957. Modern leadless pacemakers (Medtronic Micra, Abbott AVEIR) eliminate transvenous-lead failures. ICDs (Mirowski 1980 prototype, first FDA approval to CPI 1985, now Medtronic Cobalt, Abbott Gallant, Boston Sci Resonate).

10.10 Mechanical circulatory support

  • Total artificial heart: Jarvik-7 (1982, Barney Clark — DeVries at Utah; current SynCardia TAH-t).
  • LVAD: HeartMate II (Thoratec/Abbott, axial flow, 2008), HeartMate III (Abbott, centrifugal magnetically levitated rotor — FDA 2017, now standard of care for advanced HF), HeartWare HVAD (Medtronic, withdrawn 2021).

10.11 Wound care and sutures

Sutures by absorption:

  • Non-absorbable: silk (Ethicon Mersilk), nylon (Ethilon, Dermalon), polypropylene (Prolene), polyester (Ethibond), PTFE (Gore-Tex), stainless steel wire.
  • Absorbable: PGA (Dexon), polyglactin 910 PGA/PLA (Vicryl, Vicryl Rapide), PDS poly-p-dioxanone (Ethicon), poliglecaprone PGA/PCL (Monocryl), Maxon (PGA/TMC).

Wound dressings: alginate (Kaltostat), hydrocolloid (DuoDERM, ConvaTec), foam (Mepilex, Mölnlycke), silver-impregnated (Acticoat, Smith & Nephew), negative-pressure wound therapy (V.A.C., KCI/Acelity, now 3M).

10.12 Vascular access and drug delivery hardware

Central lines, ports, dialysis access grafts (W.L. Gore Propaten heparin-bonded ePTFE, Bard Carmeda), insulin pumps (Medtronic MiniMed 780G, Tandem t:slim X2, Insulet Omnipod 5), continuous glucose monitors (Dexcom G7, Abbott FreeStyle Libre 3, Medtronic Guardian 4).

11. Drug Delivery Systems

11.1 Controlled-release polymers

Higuchi (1961) and Folkman/Langer (1976) showed sustained drug release from polymeric matrices. PLGA microspheres (Lupron Depot — leuprolide PLGA, Takeda/Abbvie, FDA 1989) deliver months of GnRH agonist for prostate cancer and endometriosis. PLGA depots: Sandostatin LAR, Risperdal Consta, Trelstar.

11.2 Liposomes

Phospholipid bilayer vesicles, 50–500 nm diameter, hydrophilic interior. Doxil (Sequus → Janssen; FDA approved 1995) — pegylated liposomal doxorubicin for ovarian cancer and Kaposi sarcoma. First FDA-approved nanomedicine. Subsequent: AmBisome (amphotericin B, Gilead 1997), Marqibo (vincristine 2012), Onivyde (irinotecan 2015), Vyxeos (daunorubicin/cytarabine 2017).

11.3 Polymer micelles, dendrimers, polymeric nanoparticles

  • Genexol-PM (paclitaxel + mPEG-PDLLA micelle, Samyang, KFDA 2007).
  • Dendrimers (Tomalia at Dow 1985, Hawker, Fréchet groups) — explored for VivaGel (BCD-200 PPI dendrimer microbicide, Starpharma).
  • BIND-014 PSMA-targeted PLGA-PEG nanoparticle reached Phase 2 before BIND Biosciences bankruptcy 2016.

11.4 Antibody-drug conjugates (ADC)

Monoclonal antibody covalently linked to a cytotoxin via a cleavable linker. Mylotarg (gemtuzumab ozogamicin, Pfizer/Wyeth, FDA 2000 — withdrawn 2010, re-approved 2017), Adcetris (brentuximab vedotin, Seagen, 2011), Kadcyla (T-DM1 trastuzumab emtansine, Genentech, 2013), Enhertu (T-DXd trastuzumab deruxtecan, Daiichi/AstraZeneca 2019), Trodelvy (sacituzumab govitecan, Immunomedics/Gilead 2020).

11.5 mRNA-LNP vaccines

The breakthrough of 2020: Comirnaty / BNT162b2 (Pfizer-BioNTech, FDA EUA Dec 2020) and Spikevax / mRNA-1273 (Moderna, EUA Dec 2020) use lipid nanoparticles to deliver modified mRNA (Karikó & Weissman, Nobel 2023) encoding SARS-CoV-2 spike. LNP composition (mol%):

  • Ionizable cationic lipid (Pfizer ALC-0315 by Acuitas; Moderna SM-102) ~50%
  • Cholesterol (~38%)
  • DSPC phospholipid (~10%)
  • PEG-lipid ALC-0159 / PEG2000-DMG (~1.5%)

mRNA is encapsulated by rapid mixing in microfluidic chips (NanoAssemblr by Cytiva/Precision NanoSystems is the workhorse). The ionizable lipid is protonated at endosomal pH, disrupting the endosome to release mRNA into cytosol.

Onpattro / patisiran (Alnylam 2018) was the first siRNA-LNP approval (transthyretin amyloidosis) and validated the platform pre-COVID.

11.6 Stimuli-responsive delivery

pH-responsive (tumor acidic microenvironment, endosome), temperature-responsive (PNIPAM LCST 32 °C), redox-responsive (disulfide cleavage in cytosolic GSH), magnetic (Fe₃O₄ nanoparticle hyperthermia — NanoTherm by MagForce for glioblastoma, CE 2010), ultrasound-triggered microbubbles (Lumason, SonoVue).

11.7 Implantable depots

Norplant (levonorgestrel silicone rod 1990 — discontinued), Implanon/Nexplanon (etonogestrel EVA single rod, current), Vantas (histrelin hydrogel, Endo), Ozurdex (dexamethasone PLGA intravitreal implant, Allergan/AbbVie 2009).

12. Tissue Engineering Scaffolds

12.1 Three-pillar paradigm

Vacanti and Langer (1993) framed tissue engineering as the combination of cells + scaffold + signals (growth factors / mechanical cues). Iconic image: the “Vacanti mouse” with an auricle-shaped PGA-PLLA scaffold seeded with bovine chondrocytes, implanted subcutaneously (Cao et al. 1997).

12.2 Natural-derived scaffolds

  • Collagen (rat tail, bovine Achilles, recombinant human): Type I most common; Integra Dermal Regeneration Template (collagen-GAG with silicone backing, Yannas & Burke 1981, FDA 1996) for full-thickness burns.
  • Fibrin glue: Tisseel (Baxter), Evicel (Ethicon) for hemostasis and as cell delivery vehicle.
  • Decellularized ECM: porcine small-intestinal submucosa SIS (Cook Biotech Surgisis, OASIS Wound Matrix), human acellular dermis (LifeCell AlloDerm 1992, now Allergan/AbbVie), bovine pericardium (Synovis Peri-Strips). Doris Taylor (Minnesota → Texas Heart Institute) decellularized whole rat heart in 2008 (Nature Med), repopulated with cells — landmark in whole-organ engineering. Macchiarini’s tracheal attempts (2008, later discredited 2016) showed the perils of premature clinical translation.

12.3 Synthetic scaffolds

  • Electrospinning: PLA, PCL, PLGA, PCL/collagen blends spun into nanofiber mats (fiber diameter 100 nm–10 μm). High surface area, ECM-like topography. Used for vascular grafts (e.g., Humacyte HAV — though Humacyte uses smooth muscle cell-derived tubes, not synthetic), nerve conduits, skin substitutes.
  • 3D-printed scaffolds: stereolithography (SLA) and digital light processing (DLP) for PEGDA hydrogels; FDM/extrusion for PCL; bioprinting (cell-laden) on Organovo NovoGen, Allevi/BioBots, Cellink BIO X, RegenHU 3DDiscovery, Aspect Biosystems (microfluidic extrusion). FRESH 2.0 (Freeform Reversible Embedding of Suspended Hydrogels, Feinberg group at Carnegie Mellon 2019) prints soft hydrogels in a gelatin support bath.
  • Volumetric printing (e.g., Volumetric, Lumen Bioscience, Readily3D Tomolite): cures full 3D object in seconds via tomographic light projection — orders of magnitude faster than layer-by-layer.

12.4 Pore architecture

  • Bone scaffolds: ~70–90% porosity, 300 μm interconnected pores, surface roughness for osteoblast attachment.
  • Vascular scaffolds: 5–60 μm pores; transmural endothelialization at <40 μm pore size keeps blood-contact surface intact.
  • Nerve conduits: aligned microtopography for axonal guidance.

12.5 Growth-factor delivery in scaffolds

BMP-2 (rhBMP-2 in collagen sponge, Medtronic Infuse, FDA 2002 — controversial off-label use, 2011 Senate inquiry), PDGF (Augment Bone Graft, Wright Medical), VEGF, FGF, TGF-β. Sustained release from PLGA microspheres or affinity binding to heparin-modified scaffolds.

13. Cell Therapy and Combination Products

  • Carticel (Genzyme 1997 — first FDA-approved cell therapy, autologous chondrocyte implantation for cartilage defects); MACI (matrix-induced ACI, on porcine collagen membrane, Vericel, FDA 2016).
  • Apligraf and Dermagraft (cell-seeded skin substitutes for diabetic ulcers; Organogenesis).
  • Provenge (sipuleucel-T, Dendreon, 2010 — first cell-therapy cancer vaccine).
  • CAR-T (Kymriah Novartis 2017, Yescarta Kite/Gilead 2017) — strictly a cell therapy but combination with viral-vector materials.
  • Encapsulated islets / cell therapy adjuncts: ViaCyte PEC-Encap (now part of Vertex, encapsulating stem-cell-derived β-cells in alginate), Sernova Cell Pouch (porous PTFE).

14. Bioprinting Landscape

CompanyMethodTarget
OrganovoExtrusion (NovoGen)Liver/kidney tissue for drug testing
Cellink (BICO)Extrusion, photocuringResearch bioinks
Allevi (3D Systems)ExtrusionResearch
Aspect BiosystemsMicrofluidic extrusion (Lab-on-a-Printer)Therapeutic tissues (Novo Nordisk partnership for diabetes)
VolumetricTomographic volumetricVascularized constructs
RegenHUMulti-head extrusionResearch
Prellis BiologicsTwo-photon lithographyCapillary-resolution scaffolds
Inventia Life ScienceDrop-on-demandDrug screening
PoietisLaser-assisted (LAB)Skin
CollPlantRecombinant collagen bioinkSkin and breast scaffolds

15. Smart and Active Materials

  • Shape-memory polymers (SMPs): thermally activated self-deploying stents, vascular occluders, and minimally invasive devices (e.g., LandanCorp self-fitting orthopedic plates).
  • 4D printing: 3D-printed structures that change shape over time in response to stimuli (Lewis Lab Harvard, Tibbits MIT Self-Assembly Lab). Used for tracheal splints (Hollister, Michigan — 3D-printed PCL airway splints, first patient 2013).
  • Magnetic actuators: ferromagnetic soft robots (Boyden, Zhao MIT 2019) navigating cerebrovascular geometry; magnetic-field-actuated microrobots for drug delivery (Nelson ETH).
  • Conductive biopolymers: PEDOT:PSS, polypyrrole electrodes for neural interfaces with mechanical compliance approaching tissue.
  • Self-healing materials: explored for long-term implants, e.g., supramolecular polymers (Meijer Eindhoven, Sumerlin Florida).

16. Persistent Challenges

  • Thrombosis on blood-contact surfaces: Vroman protein cascade → platelet activation (GPIb-vWF, GPIIb/IIIa-fibrinogen) → thrombin amplification → clot. Mitigated by heparin coatings, zwitterionic polymers (sulfobetaine, MPC — Lipidure by NOF, used by Abbott Biocompatibles for stents), endothelialization, smoothness (Ra < 0.5 μm), and oral antiplatelet therapy.
  • Foreign body response: ongoing search for stealth coatings (zwitterionic, MPC, PEG) and shape/topology cues (Veiseh et al. 2015 — sphere size > 1.5 mm reduces FBR; Anderson lab MIT).
  • Aseptic loosening from wear debris: HXLPE largely solved for hips, but knee bearings remain a frontier.
  • Corrosion fatigue at modular taper junctions: especially with mixed alloys (Ti stem + Co-Cr head) — root cause of the DePuy ASR recall.
  • Infection and biofilm: 1–2% in primary arthroplasty, devastating; antibiotic-loaded PMMA cement (gentamicin), silver coatings (Stryker Hardware Silver Coating), iodine coatings (Kyocera Bonit), but no broad solution.
  • Calcification of bioprosthetic valves: still leads to ~15-year valve lifetime; anti-calcification fixation (Edwards Linx → Resilia) extends durability.
  • Vascularization of large engineered constructs: diffusion limit ~200 μm constrains scaffold thickness without prevascularization.

17. Major Companies (2024 Snapshot)

17.1 Diversified medtech

  • Medtronic (HQ Galway, Ireland / operational HQ Minneapolis): cardiac, neuromodulation, diabetes, surgical, spinal. ~$32B revenue.
  • Johnson & Johnson MedTech (DePuy Synthes for ortho, Ethicon for surgical, J&J Vision for ophthalmic).
  • Stryker (Kalamazoo, MI): hip/knee, trauma, neurotech, endoscopy.
  • Abbott: cardiovascular (St. Jude acquisition 2017), structural heart (MitraClip, TriClip), diabetes (FreeStyle Libre), neuromodulation, vascular (XIENCE).
  • Boston Scientific: cardiac rhythm (Acquired Guidant CRM 2006), structural heart (Watchman, Acurate Neo), peripheral, neuromodulation, endoscopy.
  • Becton Dickinson: needles, syringes, vascular access, diagnostics.
  • Smith & Nephew (London): ortho, sports med, advanced wound care.

17.2 Specialty

  • Zimmer Biomet: ortho.
  • Edwards Lifesciences: heart valves (TAVR Sapien dominant), critical care monitoring.
  • Cochlear Limited (Sydney, AU): cochlear implants.
  • Straumann (Basel, CH): dental.
  • Dentsply Sirona: dental.
  • Intuitive Surgical: da Vinci robotic platform.

17.3 Emerging / specialized

  • Humacyte: bioengineered acellular vessels (Symvess HAV for vascular trauma, FDA 2024).
  • Tela Bio: surgical mesh.
  • BioCardia: cardiac cell therapy delivery.
  • Anika Therapeutics: hyaluronic acid (Monovisc).
  • Organogenesis: skin substitutes.

18. Influential Academic Labs

  • Robert Langer (MIT) — controlled drug delivery, polymeric materials, tissue engineering. Co-founded Moderna, BIND, Selecta, Sigilon, dozens more.
  • David Mooney (Wyss / Harvard) — injectable scaffolds, immunoengineering, cryogels.
  • Joseph Vacanti (Mass General / Harvard) — pediatric tissue engineering, the “Vacanti mouse” with Langer.
  • Anthony Atala (Wake Forest Institute for Regenerative Medicine) — engineered bladder transplantation (Lancet 2006), bioprinting.
  • Ali Khademhosseini (Terasaki Institute) — microfluidics, organoids, hydrogels.
  • Jennifer Lewis (Wyss / Harvard) — 3D printing, vascularization (SWIFT).
  • Adam Feinberg (Carnegie Mellon) — FRESH bioprinting of soft tissue.
  • Jeffrey Karp (Brigham / Harvard) — bioinspired adhesives, drug delivery.
  • Daniel Anderson (MIT Koch) — LNP for mRNA, encapsulated cell therapy.
  • Kristi Anseth (Colorado Boulder) — PEG-based hydrogels for stem-cell biology.
  • Molly Stevens (Imperial / Oxford) — bioactive scaffolds, biosensors.
  • Samir Mitragotri (Harvard SEAS) — drug delivery, microneedles.
  • David Tirrell (Caltech) — recombinant ECM proteins.

19. Quick Reference — Common Choices

ApplicationStandard material
Hip femoral stemTi-6Al-4V (cementless) or CoCrMo (cemented)
Hip femoral headY-TZP / Biolox Delta ceramic or CoCrMo
Hip acetabular linerHXLPE with vitamin E, or ceramic
Knee femoral componentCoCrMo
Knee tibial insertHXLPE
Bone screws / platesTi-6Al-4V or 316L SS
Spinal interbody cagePEEK or 3D-printed Ti lattice
Coronary stentCo-Cr with everolimus DES coating
Heart valve (mechanical)Pyrolytic carbon (bileaflet, St. Jude/Abbott, On-X)
Heart valve (bioprosthetic)Glutaraldehyde-fixed bovine pericardium
Pacemaker canTi grade 1/2
Pacing lead conductorMP35N, insulator polyurethane or silicone
Vascular graft (large)ePTFE (Gore-Tex) or PET (Dacron)
Dental implantCP-Ti grade 4 or Y-TZP
Bone cementPMMA + BaSO₄ + gentamicin
Suture (absorbable)PGA or polyglactin 910
IOLHydrophobic acrylate (AcrySof, Tecnis)
CGM membranePolyurethane / zwitterionic
mRNA vaccine deliveryALC-0315 / SM-102 LNP

20. Adjacent

Graph View